Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

About us

We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as lung and colorectal cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.

Industry Molecular Diagnostics
Product focus Blood‐based tests for cancer detection
Products on market Epi proColon®, Epi proLung®
R&D pipeline Multiple projects in cancer detection
Technology platform DNA methylation
Patent portfolio Broad patent portfolio for DNA methylation in cancer
Founded 1998
IPO 19th July 2004
Listing Frankfurt Stock Exchange, Prime Standard: ECX
Location of business Berlin, Germany (Epigenomics AG)
Germantown, MD, and Seattle, WA, U.S.A. (Epigenomics Inc.)
Executive Board Greg Hamilton, Chief Executive Officer
Dr. Uwe Staub, Chief Operating Officer
Supervisory Board Heino von Prondzynski (Chairman)
Ann Kessler, Ph.D.
Dr. Helge Lubenow
Prof. Dr. Günther Reiter